Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Urbanski Raymond W.

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/28/2019

3. Issuer Name and Ticker or Trading Symbol

Applied BioSciences Corp. [APPB]

(Last) (First) (Middle)

C/O STONY HILL CORP., 9701 WILSHIRE BLVD, SUITE 1000

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Executive Officer /

(Street)

BEVERLY HILLS, CA 90212

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25000	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy) ⁽¹⁾	⁽²⁾	⁽³⁾	Common Stock	1000000	$1.23	D
Stock Option (right to buy) ⁽¹⁾	⁽⁴⁾	⁽⁵⁾	Common Stock	⁽⁶⁾	$1.23	D

Explanation of Responses:
(1)	Exempt transaction under SEC Rule 16b-3.
(2)	One-third of the option vests on each of the following dates: (i) May 31, 2019, (ii) April 1, 2020, and (iii) April 1, 2021.
(3)	Shares vest subject to continued employment with Applied BioSciences Corp. (the "Company"), or an affiliate thereof.
(4)	One-third (1/3) of the option vests upon the occurrence of each of the following events: (i) the Company has raised a combined $3,000,000, (ii) opening of the first IND with the FDA, or equivalent ex-US, and (iii) the Company being listed on a national securities exchange.
(5)	Shares vest subject to continued employment with the Company, or an affiliate thereof.
(6)	That number of shares of common stock equal to 3% of the Company's fully diluted common stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Urbanski Raymond W. C/O STONY HILL CORP., 9701 WILSHIRE BLVD SUITE 1000 BEVERLY HILLS, CA 90212	X		Chief Executive Officer

Signatures
/s/ Raymond Urbanski		6/4/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.